Curetis Publishes Business and Financial Update for the First Quarter 2018
in portfolio news
- Received U.S. FDA clearance for Unyvero System and LRT Cartridge
- Grew revenues in EMEA direct selling markets by 518% vs Q1 2017
- Closed EUR 4.1 million equity offering and gained access to additional USD 10 million equity facility
Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today published a business and financial update for the three months ended March 31, 2018.